<DOC>
	<DOC>NCT00430651</DOC>
	<brief_summary>This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated previously with Docetaxel.</brief_summary>
	<brief_title>Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically or cytologically confirmed NSCLC. ECOG Performance Status 02. No previous treatment with Docetaxel. Measurable Disease. Brain metastases that have been treated with radiotherapy should be stable and asymptomatic. Adequate liver kidney and bone marrow function. Patients must be able to understand the nature of this study and give written informed consent. Active cardiac disease: unstable angina or onset of angina within last 3 months, myocardial infarction within 6 months, congestive heart failure &gt; class II, cardiac ventricular arrhythmias requiring antiarrhythmic therapy. Women who are pregnant or lactating. Unknown HIV, chronic hepatitis B or chronic hepatitis C infections. Serious neurologic or psychiatric disease. Second primary malignancy within the past 5 years, except nonmelanomas skin cancer or in situ carcinoma of the cervix. Active uncontrolled infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Non Small Cell Lung Cancer</keyword>
	<keyword>2nd line chemotherapy</keyword>
	<keyword>Docetaxel</keyword>
</DOC>